Intracameral triamcinolone acetonide as treatment for endothelial allograft rejection after penetrating keratoplasty.
| Autor: | Maris PJ Jr; Department of Ophthalmology, Nassau University Medical Center, East Meadow, NY, USA. pmaris@msn.com, Correnti AJ, Donnenfeld ED |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cornea [Cornea] 2008 Aug; Vol. 27 (7), pp. 847-50. |
| DOI: | 10.1097/ICO.0b013e31816b69f5 |
| Abstrakt: | Purpose: Intracameral injection of triamcinolone acetonide as treatment of therapy-resistant endothelial allograft rejection after penetrating keratoplasty is reported. Methods: A 32-year-old patient showed conventional therapy-resistant endothelial allograft rejection 2 months after penetrating keratoplasty. The patient received an intracameral injection of 4 mg in 0.1 mL of triamcinolone acetonide. Preinjection visual acuity was count fingers at 3 ft, and the graft showed diffuse haze and multiple endothelial rejection lines. Results: Within 2 weeks after injection, marked resolution of the microcystic edema and reversal of the endothelial rejection was noted. Fourteen months after injection, best-corrected visual acuity was 20/20, and intraocular pressure was 17 mm Hg without antiglaucoma therapy. Conclusions: Intracameral injection of triamcinolone acetonide may be an additional treatment modality in the treatment of endothelial allograft rejection when traditional steroid therapies have failed. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|